Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)

PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions

Ulcerative Colitis

Interventions

DRUG

LT-02

LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily

DRUG

Placebo

LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily

DRUG

Mesalamine

LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily

Trial Locations (1)

Agaplesion Markus-Krankenhaus, Frankfurt a.M.